SCHEMBL5017451

SCHEMBL5017451

CCO[C@@H](Cc1ccc(O)cc1C(F)(F)F)C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 9/20 0.39
PPARG P37231 6/20 0.39
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
MIF P14174 1/20 0.35
STIM1 Q13586 1/20 0.35
ORAI1 Q96D31 1/20 0.35
ORAI3 Q9BRQ5 1/20 0.35
ALOX5 P09917 1/20 0.35
POLQ O75417 1/20 0.34
ESRRG P62508 1/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA7 P43166 2/20 0.34
CA9 Q16790 2/20 0.34
CA14 Q9ULX7 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5085176 1.00 EPHX2 (0.39) EPHX2PPARGPPARDPPARAESR1
SCHEMBL3374300 0.83 CHRNA7 (0.38) PPARAESR1ESR2MIFALOX5
SCHEMBL3372979 0.83 ESR1 (0.39) PPARGPPARAESR1ESR2MIF
SCHEMBL3402960 0.83 ESR1 (0.39) PPARGPPARAESR1ESR2MIF
SCHEMBL3371001 0.82 NR3C1 (0.43) ESR1ESR2MIFCA12CA1
SCHEMBL5017407 0.82 NR3C1 (0.43) ESR1ESR2MIFCA12CA1
SCHEMBL5022444 0.81 PPARG (0.49) EPHX2PPARGPPARDPPARA
SCHEMBL5095387 0.81 APP (0.42) ESR1ESR2MIFALOX5CA12
SCHEMBL3370534 0.81 CYP3A4 (0.39) PPARGPPARAESR1ESR2MIF
SCHEMBL3372793 0.81 APP (0.42) ESR1ESR2MIFALOX5CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551814-B1 CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-23 EP disclosed
US-7348349-B2 Oxazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-03-25 US disclosed
US-20050267180-A1 Novel oxazole derivatives BINGGELI ALFRED 2005-12-01 US disclosed
US-6969725-B2 Oxazole derivatives HOFFMAN-LA ROCHE INC. (US) 2005-11-29 US disclosed
EP-1551814-A1 CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-07-13 EP disclosed
US-20040116487-A1 Novel oxazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-17 US disclosed
WO-2004031162-A1 CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267180-A1 Novel oxazole derivatives NR1H3, NR1H2, PPARD EPHX2 3000/4885PPARG 7/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.